💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, trading cheap versus its own history.
Pfizer is scored on the pharma / healthcare framework. It keeps a fat 26.7% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.34× reported profit. Free cash flow is worth about 2.3% of its market value.
Over the last 3 years revenue compounded at 2%/yr and profit at 5%/yr. Book value has grown 9%/yr. Return on equity is an elite 19.8%. In the latest quarter profit grew 2% versus the prior quarter.
At 24× earnings, the stock sits at the 4th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~9%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 20.5 | — | — |
| P/B | 4.02 | 4.11 | better |
| EV/EBITDA | 11.96 | 19.15 | better |
| ROE | 19.78 | — | — |
| ROCE | 27.27 | 6.87 | better |
| ROA | 33.25 | — | — |
| Quick Ratio | 5.31 | 4.8 | better |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
2% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Operating margin has expanded from 33% to 36% — the business is keeping more of each rupee earned.
ROE at 17% — a respectable return on shareholder capital. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Low variance across years — a predictable business that earns steadily on its equity base.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 5% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.3× PAT — earnings are well-backed by cash; strong accrual quality. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (4% spread) — a predictable, non-seasonal revenue stream.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 63.9% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.